Active, not recruitingPhase 2NCT05026905

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

Studying Multiple endocrine neoplasia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Health Research Institutes, Taiwan
Principal Investigator
Li-Tzong Chen, MD, Ph.D.
National Health Research Institutes, Taiwan
Intervention
Gemcitabine 1000 mg(drug)
Enrollment
66 enrolled
Eligibility
20 years · All sexes
Timeline
2021 – 2027

Study locations (4)

Collaborators

China Medical University Hospital · National Cheng-Kung University Hospital · Kaohsiung Medical University Chung-Ho Memorial Hospital · Taichung Veterans General Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05026905 on ClinicalTrials.gov

Other trials for Multiple endocrine neoplasia

Additional recruiting or active studies for the same condition.

See all trials for Multiple endocrine neoplasia →

← Back to all trials